IL308853A - A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor - Google Patents

A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor

Info

Publication number
IL308853A
IL308853A IL308853A IL30885323A IL308853A IL 308853 A IL308853 A IL 308853A IL 308853 A IL308853 A IL 308853A IL 30885323 A IL30885323 A IL 30885323A IL 308853 A IL308853 A IL 308853A
Authority
IL
Israel
Prior art keywords
methyl
amino
trifluoromethyl
inhibitor
pyridinyl
Prior art date
Application number
IL308853A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Patrick Dillon
Claire L Neilan
Marcus Michael Fischer
Kimberline Yang Gerrick
Original Assignee
Ideaya Biosciences Inc
Michael Patrick Dillon
Claire L Neilan
Marcus Michael Fischer
Kimberline Yang Gerrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc, Michael Patrick Dillon, Claire L Neilan, Marcus Michael Fischer, Kimberline Yang Gerrick filed Critical Ideaya Biosciences Inc
Publication of IL308853A publication Critical patent/IL308853A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL308853A 2021-06-02 2022-06-01 A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor IL308853A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163196008P 2021-06-02 2021-06-02
US202263362438P 2022-04-04 2022-04-04
US202263364360P 2022-05-09 2022-05-09
PCT/US2022/072693 WO2022256806A1 (en) 2021-06-02 2022-06-01 Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor

Publications (1)

Publication Number Publication Date
IL308853A true IL308853A (en) 2024-01-01

Family

ID=84323602

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308853A IL308853A (en) 2021-06-02 2022-06-01 A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor

Country Status (11)

Country Link
US (2) US20240108626A1 (enExample)
EP (1) EP4347569A4 (enExample)
JP (1) JP2024521920A (enExample)
KR (1) KR20240019172A (enExample)
AU (1) AU2022287057A1 (enExample)
BR (1) BR112023025360A2 (enExample)
CA (1) CA3220160A1 (enExample)
CL (1) CL2023003603A1 (enExample)
IL (1) IL308853A (enExample)
MX (1) MX2023014405A (enExample)
WO (1) WO2022256806A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
EP4347569A4 (en) * 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
WO2023125540A1 (zh) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 吡唑-1(2h)-酞嗪酮类化合物及其应用
EP4469447A1 (en) * 2022-01-26 2024-12-04 Tango Therapeutics, Inc. Compounds and methods of use
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
WO2023246873A1 (zh) * 2022-06-23 2023-12-28 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
EP4549440A4 (en) * 2022-07-01 2026-04-22 Cytosinlab Therapeutics Co Ltd CLASS OF PRMT5 INHIBITORS AND THEIR USES
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
AU2023366908A1 (en) * 2022-10-25 2025-05-08 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用mta協作的prmt5抑制劑和mat2a抑制劑之癌症治療
CN120457124A (zh) * 2022-12-30 2025-08-08 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
CN120476118A (zh) * 2023-01-17 2025-08-12 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
MX2025012140A (es) * 2023-04-13 2026-02-03 Ideaya Biosciences Inc Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de la topoisomerasa, un inhibidor del empalme sulfonamida, o un inhibidor de kif18
TW202442231A (zh) * 2023-04-28 2024-11-01 智擎生技製藥股份有限公司 Mta協同性prmt5抑制劑
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN121646468A (zh) * 2023-08-08 2026-03-10 米拉蒂治疗公司 用于治疗恶性周围神经鞘瘤的方法和组合物
WO2025059579A1 (en) * 2023-09-15 2025-03-20 Ideaya Biosciences, Inc. Methods of treating mat2a related diseases
WO2025061102A1 (zh) * 2023-09-20 2025-03-27 西藏海思科制药有限公司 一种含氰基的杂环化合物及其用途
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025098450A1 (zh) * 2023-11-08 2025-05-15 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
WO2025113704A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
WO2025157286A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和mat2a抑制剂的药物组合物
WO2025166308A1 (en) * 2024-01-31 2025-08-07 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217297A1 (en) * 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096165A1 (en) * 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2020123395A1 (en) * 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
IL290341B2 (en) * 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US12403137B2 (en) * 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
EP4347569A4 (en) * 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor

Also Published As

Publication number Publication date
US12115163B2 (en) 2024-10-15
WO2022256806A1 (en) 2022-12-08
KR20240019172A (ko) 2024-02-14
US20240173326A1 (en) 2024-05-30
JP2024521920A (ja) 2024-06-04
CL2023003603A1 (es) 2024-07-12
US20240108626A1 (en) 2024-04-04
AU2022287057A1 (en) 2023-12-14
EP4347569A1 (en) 2024-04-10
BR112023025360A2 (pt) 2024-02-20
CA3220160A1 (en) 2022-12-08
MX2023014405A (es) 2024-04-30
EP4347569A4 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
US12115163B2 (en) Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
US20240269143A1 (en) Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor
US11084798B1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US12084429B2 (en) Fused ring compounds
CN114456175B (zh) 作为tam抑制剂的吡咯并三嗪化合物
TW202304934A (zh) 非環氧氮呯化合物及其用途
EP2364302B1 (en) Triazine analogs and their use as therapeutic agents and diagnostic probes
KR102816365B1 (ko) 피라진 화합물 및 이의 용도
JP2022515198A (ja) FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
JP7723666B2 (ja) 環式化合物およびその使用方法
US20180250400A1 (en) Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor
EP4334298A1 (en) Urea derivatives which can be used to treat cancer
WO2005094830A1 (en) Combinations of signal transduction inhibitors
EP1942900A2 (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
CA2921959A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US20230133671A1 (en) Setd2 inhibitors and related methods and uses, including combination therapies
US20240299352A1 (en) Combination therapies with setd2 inhibitors
WO2024020534A2 (en) Cyclic compounds and methods of using same
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
RU2809631C2 (ru) Пиразиновые соединения и их применения
JP2020537661A (ja) ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用
WO2024227033A1 (en) Heterocyclic compounds as parp1 inhibitors
CN121752567A (zh) 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物
CA3259052A1 (en) HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS.
EA052528B1 (ru) Циклические соединения и способы их применения